{
  "id": "5a74b1730384be9551000007",
  "type": "factoid",
  "question": "Which retinal dystrophy related gene is targeted by the AAV2-hRPE65v2 drug?",
  "ideal_answer": "AAV2-hRPE65v2, also called voretigene neparvovec, targets the RPE65 gene, whose mutations lead to retinal dystrophy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28712537"
  ],
  "snippets": [
    {
      "text": "Voretigene neparvovec gene replacement improved functional vision in RPE65-mediated inherited retinal dystrophy previously medically untreatable.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28712537",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this open-label, randomised, controlled phase 3 trial done at two sites in the USA, individuals aged 3 years or older with, in each eye, best corrected visual acuity of 20/60 or worse, or visual field less than 20 degrees in any meridian, or both, with confirmed genetic diagnosis of biallelic RPE65 mutations, sufficient viable retina, and ability to perform standardised multi-luminance mobility testing (MLMT) within the luminance range evaluated, were eligible. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28712537",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28712537",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "RPE65"
}